Alaunos Therapeutics Files Q3 2024 10-Q
Ticker: TCRT · Form: 10-Q · Filed: Nov 14, 2024 · CIK: 1107421
| Field | Detail |
|---|---|
| Company | Alaunos Therapeutics, INC. (TCRT) |
| Form Type | 10-Q |
| Filed Date | Nov 14, 2024 |
| Risk Level | medium |
| Pages | 15 |
| Reading Time | 18 min |
| Key Dollar Amounts | $0.001, $2,500,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, biotechnology, financials, R&D
TL;DR
Alaunos Therapeutics filed its Q3 2024 10-Q, detailing financials and R&D progress.
AI Summary
Alaunos Therapeutics, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported on its financial performance and operational activities, including its ongoing research and development efforts. Key financial data and business updates are detailed within the filing.
Why It Matters
This filing provides investors with a crucial update on Alaunos Therapeutics' financial health and operational progress, impacting investment decisions.
Risk Assessment
Risk Level: medium — As a biotechnology company, Alaunos Therapeutics faces inherent risks related to drug development, regulatory approvals, and market competition.
Key Numbers
- 2024-09-30 — Reporting Period End Date (The end date for the financial and operational data presented in the 10-Q.)
- 2024-11-14 — Filing Date (The date the 10-Q was officially submitted to the SEC.)
- 2024-01-01 — Fiscal Year Start Date (The beginning of the fiscal year for which the report is filed.)
Key Players & Entities
- Alaunos Therapeutics, Inc. (company) — Filer of the 10-Q
- ZIOPHARM ONCOLOGY INC (company) — Former company name
- EASYWEB INC (company) — Former company name
- National Cancer Institute (company) — Licensing partner
- Dune Lake Capital (company) — Financial entity mentioned
- EdenBiocell (company) — Entity mentioned
FAQ
What was the primary focus of Alaunos Therapeutics' research and development activities during the period ending September 30, 2024?
The filing mentions activities related to 'LicenseAgreementWithTheNationalCancerInstituteMember' for the periods 2024-01-01 to 2024-09-30 and 2023-01-01 to 2023-09-30, indicating ongoing R&D in that area.
Has Alaunos Therapeutics undergone any name changes in its history?
Yes, the company was formerly known as ZIOPHARM ONCOLOGY INC (name change date 2005-09-19) and prior to that, EASYWEB INC (name change date 2001-02-13).
What is the standard industrial classification for Alaunos Therapeutics, Inc.?
The company's Standard Industrial Classification is 'PHARMACEUTICAL PREPARATIONS [2834]'.
When did Alaunos Therapeutics' fiscal year end?
The company's fiscal year ends on December 31 (1231).
What is the business address of Alaunos Therapeutics, Inc.?
The business address is 2617 Bissonnet St, Suite 225, Houston, TX 77005.
Filing Stats: 4,466 words · 18 min read · ~15 pages · Grade level 18 · Accepted 2024-11-14 09:30:30
Key Financial Figures
- $0.001 — hares of the registrant's common stock, $0.001 par value, was 1,601,252 shares. SPEC
- $2,500,000 — in our shareholder equity falling below $2,500,000 as required by Nasdaq Listing Rule 5550
Filing Documents
- tcrt-20240930.htm (10-Q) — 1350KB
- tcrt-ex31_1.htm (EX-31.1) — 13KB
- tcrt-ex32_1.htm (EX-32.1) — 7KB
- 0000950170-24-126793.txt ( ) — 4133KB
- tcrt-20240930.xsd (EX-101.SCH) — 596KB
- tcrt-20240930_htm.xml (XML) — 436KB
Management's Discussion and Analysis of Financial Condition and Results of Operations
Management's Discussion and Analysis of Financial Condition and Results of Operations 15 Item 3.
Quantitative and Qualitative Disclosures about Market Risk
Quantitative and Qualitative Disclosures about Market Risk 21 Item 4.
Controls and Procedures
Controls and Procedures 21 PART II. OTHER INFORMATION Item 1.
Legal Proceedings
Legal Proceedings 22 Item 1A.
Risk Factors
Risk Factors 22 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 49 Item 3. Defaults Upon Senior Securities 49 Item 4. Mine Safety Disclosures 49 Item 5. Other Information 49 Item 6. Exhibits 51 1
—FINANCIAL INFORMATION
PART I—FINANCIAL INFORMATION
Condensed Financial Statements
Item 1. Condensed Financial Statements Alaunos Therapeutics, Inc. CONDENSED BALANCE SHEETS (unaudited) (in thousands, except share and per share data) September 30, December 31, 2024 2023 ASSETS: Current assets: Cash and cash equivalents $ 1,683 $ 6,062 Receivables — 1 Prepaid expenses and other current assets 1,867 2,198 Total current assets 3,550 8,261 Property and equipment, net — 2 Total assets $ 3,550 $ 8,263 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable $ 458 $ 616 Accrued expenses 368 1,340 Total current liabilities 826 1,956 Total liabilities $ 826 $ 1,956 Commitments and contingencies Stockholders' equity Common stock $ 0.001 par value; 5,000,000 shares authorized, 1,601,252 shares issued and outstanding at September 30, 2024 and at December 31, 2023 2 2 Additional paid-in capital 922,426 922,072 Accumulated deficit ( 919,704 ) ( 915,767 ) Total stockholders' equity 2,724 6,307 Total liabilities and stockholders' equity $ 3,550 $ 8,263 The accompanying notes are an integral part of these condensed financial statements. 2 Alaunos Therapeutics, Inc. CONDENSED STATEMENTS OF OPERATIONS (unaudited) (in thousands, except share and per share data) For the Three Months Ended September 30, For the Nine Months Ended September 30, 2024 2023 2024 2023 Revenue $ — $ — $ 6 $ 4 Operating expenses: Research and development 143 3,656 448 15,346 General and administrative 1,007 3,578 3,615 9,791 Gain on lease modification — — — ( 245 ) Restructuring costs — 419 — 419 Property and equipment and right-of-use asset impairment — 1,011 — 1,011 Total operating expenses 1,150 8,664 4,063 26,322 Loss from operations ( 1,150 ) ( 8,664 ) ( 4,057 ) ( 26,318 ) Other income (expense): Interest